Madhavi Lakkaraja, MD, MPH Fred Hutchinson Cancer Center, University of Washington School of Medicine United States From ISCT 2025 Roundtable Session: Cell Therapies to Manage GVHD - Learning From Pivotal Approvals 1. How the Biology of Acute Graft Versus Host Disease (GVHD) Makes It...
Hannah Song, PhD Contributing Editor, ISCT Telegraft National Institutes of Health United States It is my great honor and privilege to write to you today as a newly-minted Telegraft Editorial Board member! I’ve been part of the ISCT community for 5 years and involved in cell and gene...
Rajdeep Das, MD, PhD, FIBMS Member, ISCT Lab Practices Committee University Hospitals Cleveland Medical Center United States Karen E. Martin, PhD Department of Biomedial Engineering Tufts University United States Medhat Askar, MD, PhD, MSHPE, FRCPath Member, ISCT Lab Practices...
Shyam Bhakta, MD, MBA Contributing Editor, ISCT Telegraft United States Dr. Mary Laughlin grew up in Buffalo, NY, where the Roswell Park Cancer Center and Institute is located and where she also completed an internship while in high school. Dr. Laughlin says that at the time, Roswell...
Advanced therapy development is no longer limited by whether the science can work. Platform technologies are established, translational pathways are better understood, and the distance between discovery and first-in-human continues to shrink. What now limits progress for many programs is the...
ISCT Mesenchymal Stromal Cell (MSC) Committee Mesenchymal stromal cells (MSCs) are among the most widely used cellular products worldwide, yet the field still lacks shared, testable answers about what happens to these cells after administration. A new ISCT MSC Committee-led perspective (...
Andrew Haskell, PhD, MLS, CT(ASCP)CM, MBCM, QLSCM ISCT North America LRA Committee United States Lynn Csontos, RAC ISCT North America LRA Committee STEMCELL Technologies Canada Kevin Bosse, PhD, RAC-US, CABP(H) Chair, ISCT North America LRA Committee ISCT North America Regional...
Fajar Dumadi, BSc ISCT Canada Committee for Advanced Therapies (CAT) Agendas for recent meetings Agenda for the meeting on 18-20 March 2026 https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-18-20-march-2026 en.pdf Agenda for the meeting on 18-20 February...
Mirja Krause-Onwukwe, PhD, MSc ISCT ANZ LRA Committee Member Australia Gabrielle O'Sullivan, PhD ISCT ANZ LRA Committee Co-Chair Australia Australia and New Zealand Regulatory Updates Medsafe Medsafe Guidance on Advanced Therapies – As an outcome of the consultation...
Fajar Dumadi, BSc Specialist, Regulatory Program ISCT Canada With great excitement, the International Society for Cell & Gene Therapy (ISCT) publishes its fifth Global Regulatory Report in collaboration with Clarivate ™. This report offers a comprehensive global overview of the cell...